Evaluating the Science of Cardiogenic Shock

Slides:



Advertisements
Similar presentations
Inequalities across Europe in access to primary angioplasty to treat acute heart attack patients -the cross-border dimension- John Martin, MD, FRCP, FESC,
Advertisements

IABP用于高危PCI有价值吗? Is IABP Valuable for High-Risk PCI?
Floriane Zeyons, MD University Hospital of Strasbourg, France
Improving Outcomes in Cardiogenic Shock
Abiomed ELAB Meeting March 3, 2017
Assist Devices for the Treatment of Cardiogenic Shock
Role of ECMO in Acute Cardiogenic Shock
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
circulatory support in cardiogenic shock
Impella 2.5® Device Is Associated with Improved Survival in AMICS
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
Exploring Early Combination Therapy in PAH
Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.
PCSK9 Inhibitors Post-CVOTs
NOACs for Cancer-Associated Thrombosis:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
Omega-3 Prescriptions vs Supplements in Practice
Optimizing Outcomes in Short Bowel Syndrome With IF
Acute Heart Failure.
Advances in Management of Perioperative Hypotension: It Takes a Team
Cardiogenic Shock.
The Clinical Enigma of Cardiogenic Shock
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
Heart Failure and Hospital Readmissions
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
Best Practices in Huntington Disease
Addressing Iron Deficiency in Chronic HF
Program Goal. Program Goal Current Stroke Guidelines: AHA/ASA.
Percutaneous Mechanical Circulatory Support Devices
Part II: It Takes a Team— Incorporating High-Sensitivity Troponin Into Clinical Care.
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Chronic Idiopathic Urticaria
Heart Failure Prevention: Mission Impossible?
Treatment Options to Consider
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Tackling CV Risk in T2DM.
Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.
A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Exploring Statin Intolerance
Atrial Fibrillation.
Treating CD30-Expressing Cutaneous T-Cell Lymphoma
Taking the "Cryptogenic" Out of Cryptogenic Stroke
Physiology Myocardial Oxygen Supply and Demanda,b.
Aspirin and Cardioprevention in 2018
Primary PCI Monitoring Performance
What's New in Therapeutic Options for Moderate to Severe RA?
The European Society of Cardiology Presented by RJ De Winter
New Strategies to Reduce HF Readmissions
Managing HF in Primary Care
Global Registry of Acute Coronary Events: GRACE
Iron Deficiency in Heart Failure
A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.
PeaceHealth Southwest Hospital/Carson Tahoe Medical Center
Program Goals Background: Anticoagulation in Patients With VTE.
Perspective on the Multidisciplinary Management of PAH
Strengthening Lung Cancer Team Connections to Improve Outcomes With Immunotherapy.
Taking the "Cryptogenic" Out of Cryptogenic Stroke
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
Pulmonary Arterial Hypertension and Hospitalizations
Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.
ESC Guideline on the Management of STEMI Recommendation for DAPT
Anemia Explored.
Managing HF in Primary Care
My PAH Patient.
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Rethinking Risk Stratification for Nonischemic HF:
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Evaluating the Science of Cardiogenic Shock

Introduction

Coordination of Care for Cardiogenic Shock Team Approach

Potential Cardiogenic Shock Care Pathway, Location and Providers

Cardiogenic Shock Care Multidisciplinary Team

Elements of Cardiogenic Shock Team

Ensuring Patients Are Referred or Seen at the Right Time

Cardiogenic Shock Center Characteristics 2017 AHA Scientific Statement

Trends in MCS Use and Hospital Mortality

IABP-SHOCK II Trial

Role of Temporary MCS Patient and Programmatic Considerations

Clinical Considerations for Device Selection Short-Term MCS

Recent Meta-Analyses

Need for Randomized Controlled Data

Recommendation for IABP Use US vs European Guidelines

Relevant Guidelines for Non-AMI Cardiogenic Shock

Management of AMI in ST-Segment Elevation 2017 ESC European Guidelines

Management of ST-Elevation MI US Guideline: 2013 ACCF/AHA

Importance of Early Recognition and Stabilization

Outcomes in Cardiogenic Shock IMPRESS Trial, CULPRIT-SHOCK Trial

Refractory VF/VT Out-of-Hospital Cardiac Arrest Critical Care Strategies and Outcomes

Key Considerations

Patient Characteristics and Impact of Timing of IABP Retrospective Analysis

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)